Siokas V, Aloizou AM, Liampas I, Bakirtzis C, Nasios G, Paterakis K, Sgantzos M, Bogdanos DP, Spandidos DA, Tsatsakis A, Mitsias PD, and Dardiotis E. Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis. Mol Med Rep 2022; 25(4).
Mol Med Rep
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Through a genome‑wide association study (GWAS), the Sec1 family domain‑containing protein 1 (SCFD1) rs10139154 variant at 14q12 has emerged as a risk factor gene for ALS. Moreover, it has been reported to influence the age at onset (AAO) of patients with ALS. The aim of the present study was to assess the association of the SCFD1 rs10139154 polymorphism with the risk of developing ALS. For this purpose, 155 patients with sporadic ALS and 155 healthy controls were genotyped for the SCFD1 rs10139154. The effect of the SCFD1 rs10139154 polymorphism was then examined on the following parameters: i) The risk of developing ALS; ii) the AAO of ALS; iii) the site of ALS onset (patients with bulbar onset ALS vs. healthy controls; and patients with limb onset ALS vs. healthy controls); and iv) the AAO of ALS onset with subgroup analyses based on the site of onset (bulbar and limb, crude and adjusted for sex). The analysis of all the outcomes was performed assuming five genetic models. Crude and adjusted analyses were applied. The threshold for statistical significance was set at 0.05. The results revealed no association between SCFD1 rs10139154 and any of the examined phenotypes in any of the models examined. On the whole, based on the findings of the present study, SCFD1 rs10139154 does not appear to play a determining role in the risk of developing ALS.
Medical Subject Headings
Adaptor Proteins, Vesicular Transport; Amyotrophic Lateral Sclerosis; Genome-Wide Association Study; Genotype; Humans; Neurodegenerative Diseases; Polymorphism, Single Nucleotide